Literature DB >> 23497917

Chitosan based advanced hemostatic dressing is associated with decreased blood loss in a swine uncontrolled hemorrhage model.

Nicholas R Kunio1, Gordon M Riha, Katherine M Watson, Jerome A Differding, Martin A Schreiber, Jennifer M Watters.   

Abstract

BACKGROUND: The purpose of this study was to compare standard gauze (SG) and advanced hemostatic dressings in use by military personnel in a no-hold model.
METHODS: A randomized, controlled trial was conducted using 36 swine. Animals underwent femoral arteriotomy, followed by 60 seconds of uncontrolled hemorrhage. After hemorrhage, packing with 1 of 3 dressings-SG, Combat Gauze (CG), or Celox Rapid gauze (XG)-and a 500-mL bolus of Hextend were initiated. Pressure was not held after packing, and animals were followed for 120 minutes. Physiologic parameters were monitored continuously, and electrolyte and hematologic laboratory assessments were performed before injury and 30 and 120 minutes after injury. Dressing failure was determined if bleeding occurred outside the wound.
RESULTS: All animals survived to study end. Baseline characteristics were similar between groups. No statistical difference was seen in initial blood loss or dressing success rate (SG, 10 of 12; CG, 10 of 12; and XG, 12 of 12). Secondary blood loss was significantly less with XG (median, 12.8 mL; interquartile range, 8.8 to 39.7 mL) compared with SG (median, 44.7 mL; interquartile range, 17.8 to 85.3 mL; P = .02) and CG (median, 31.9 mL; interquartile range, 18.6 to 69.1 mL; P = .05). Packing time was significantly shorter with XG (mean, 37.1 ± 6.2 seconds) compared with SG (mean, 45.2 ± 6.0 seconds; P < .01) and CG (mean, 43.5 ± 5.6 seconds; P = .01).
CONCLUSIONS: XG demonstrated shorter application time and decreased secondary blood loss in comparison with both SG and CG. These differences may be of potential benefit in a care-under-fire scenario.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23497917     DOI: 10.1016/j.amjsurg.2013.01.014

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  Evaluation of a photocrosslinkable hydroxyethyl chitosan hydrogel as a potential drug release system for glaucoma surgery.

Authors:  Xuesong Qiao; Xiaoting Peng; Jing Qiao; Zhiwen Jiang; Baoqin Han; Chaozhong Yang; Wanshun Liu
Journal:  J Mater Sci Mater Med       Date:  2017-08-22       Impact factor: 3.896

Review 2.  Biomaterials for Hemostasis.

Authors:  Aryssa Simpson; Anita Shukla; Ashley C Brown
Journal:  Annu Rev Biomed Eng       Date:  2022-03-01       Impact factor: 11.324

Review 3.  [Hemostyptics for treatment of junctional vascular injuries : Management of traumatic vascular injuries at the transition from trunk to extremities].

Authors:  D C Hinck; S Wipper; E S Debus
Journal:  Unfallchirurg       Date:  2018-07       Impact factor: 1.000

4.  Cellulose fibers-reinforced self-expanding porous composite with multiple hemostatic efficacy and shape adaptability for uncontrollable massive hemorrhage treatment.

Authors:  Yansen Wang; Yifan Zhao; Longxue Qiao; Faxing Zou; Yajie Xie; Yudong Zheng; Yong Chao; Ying Yang; Wei He; Siming Yang
Journal:  Bioact Mater       Date:  2021-01-11

5.  Preparation of Super Absorbent and Highly Active Fish Collagen Sponge and its Hemostatic Effect in vivo and in vitro.

Authors:  Lei Wang; Wenjun Li; Yan Qu; Kai Wang; Kangning Lv; Xiaoli He; Song Qin
Journal:  Front Bioeng Biotechnol       Date:  2022-03-10

Review 6.  Chitosan-Based Composite Materials for Prospective Hemostatic Applications.

Authors:  Zhang Hu; Dong-Ying Zhang; Si-Tong Lu; Pu-Wang Li; Si-Dong Li
Journal:  Mar Drugs       Date:  2018-08-04       Impact factor: 5.118

7.  The Comparative Immunotropic Activity of Carrageenan, Chitosan and Their Complexes.

Authors:  Viktoriya N Davydova; Irina V Sorokina; Aleksandra V Volod'ko; Ekaterina V Sokolova; Marina S Borisova; Irina M Yermak
Journal:  Mar Drugs       Date:  2020-09-04       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.